Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quad Pharmaceuticals sale

Executive Summary

T&S Holding signs a non-binding letter of intent to acquire "substantially all" the assets of injectable generics firm Quad, parent Pharmaceutical Resources, Inc. announces Jan. 14. Quad has nine active ANDAs remaining after asking FDA to withdraw 97 of its previous 106 ANDAs in November. In return for Quad's assets, privately-held T&S Holding will assume debt of approximately $3 mil., make future payments of up to $1.55 mil. based on sales of the products acquired, and make cash payments totaling $750,000. The deal is expected to close in April 1992, subject to T&S Holding obtaining financing. PRI announced last September that Quad's operations were being discontinued and that it planned to sell the generic injectables subsidiary ("The Pink Sheet" Sept. 30, T&G-11)....

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts